(Press-News.org) Hot flashes, night sweats and sleep disturbances are common symptoms of menopause that can affect health, quality of life and work productivity. A new review published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.221438 recommends menopausal hormone therapy, historically known as hormone replacement therapy (HRT), as first-line treatment in people without risk factors.
Menopausal symptoms may occur up to 10 years before the last menstrual period and can last more than 10 years, with negative effects for many people.
"Menopause and perimenopause can be associated with distressing symptoms and reduced quality of life," writes Dr. Iliana Lega, Women's College Hospital and the University of Toronto, Toronto, Ontario, with coauthors. "Menopausal hormone therapy is the first-line treatment for vasomotor symptoms in the absence of contraindications."
The review summarizes the latest evidence for diagnosing and treating menopausal symptoms as well as the risks and benefits of therapies to help clinicians and patients manage the condition.
"Although many treatments exist for menopausal symptoms, fears around the risks of menopausal hormone therapy and lack of knowledge regarding treatment options often impede patients from receiving treatment," write the authors.
Benefits of menopausal hormone therapy include
reduced hot flashes in as many as 90% of patients with moderate to severe symptoms;
improved blood lipid levels and a possible reduced risk of diabetes; and
fewer fragility fractures of the hip, spine and other bones.
What about the risks?
Although previous evidence has shown an increased risk of breast cancer, the risk is much lower in people aged 50–59 years and in those who start menopausal hormone therapy in the first 10 years of menopause.
Some studies show an increased risk of ischemic stroke in women older than 60 years who start therapy 10 years after the start of menopause, but the risk is low for those younger than 60.
For people with risk factors or those who do not want to take menopausal hormone therapy, nonhormonal therapies, such as some selective serotonin reuptake inhibitors (SSRIs) and other medications, can help alleviate symptoms.
"Despite early concerns of an increased risk of cardiovascular events with menopausal hormone therapy after the Women's Health Initiative trial, increasing evidence shows a possible reduction in coronary artery disease with menopausal hormone therapy among younger menopausal patients, specifically those who start menopausal hormone therapy before age 60 years or within 10 years of menopause," write the authors.
They emphasize that it's important for clinicians to ask about symptoms before and during menopause and to discuss treatments with patients based on their personal preferences and potential risk factors.
END
Managing menopause: Hormone therapy is back
2023-05-15
ELSE PRESS RELEASES FROM THIS DATE:
Can’t find your phone? There’s a robot for that
2023-05-15
Engineers at the University of Waterloo have discovered a new way to program robots to help people with dementia locate medicine, glasses, phones and other objects they need but have lost.
And while the initial focus is on assisting a specific group of people, the technology could someday be used by anyone who has searched high and low for something they’ve misplaced.
“The long-term impact of this is really exciting,” said Dr. Ali Ayub, a post-doctoral fellow in electrical and computer engineering. “A user can be involved not just with a companion robot but a personalized ...
Study shows how both metabolically healthy and unhealthy ‘forms’ of obesity increase risk of various obesity-related cancers
2023-05-14
**Note: the release below is a special early release from the European Congress on Obesity (ECO, Dublin, 17-20 May). Please credit the conference if you use this story**
New research to be presented at this coming week’s European Congress on Obesity in Dublin, Ireland (17-20 May) and published in the Journal of the National Cancer Institute shows that both the metabolically healthy and unhealthy ‘forms’ of obesity are associated with an increased risk of various obesity-related cancers, with the relationship stronger in metabolically unhealthy obesity. The study is by Dr Ming Sun, Lund University, Malmö, ...
Clinically relevant deficiency of the “bonding hormone” oxytocin demonstrated
2023-05-14
The hormone oxytocin is important for social interaction and to control emotions. A deficiency of this hormone has previously been assumed in various diseases such as autism, but has never been proven. Now, for the first time, researchers from the University of Basel and the University Hospital of Basel have succeeded in demonstrating a deficiency of oxytocin in patients with a deficiency of vasopressin caused by a disease of the pituitary gland. This finding could be key to developing new therapeutic approaches.
The hormones oxytocin and vasopressin are produced in the same area of the brain ...
Addiction scientists seek to better understand cocaine use disorder: ‘Stimulants are coming back’
2023-05-14
Nearly 2 percent of the U.S. population reported cocaine use in 2020, and the highly addictive substance was involved in nearly one in five overdose deaths, according to the Centers for Disease Control.
In Virginia, the number of cocaine-related overdoses has been increasing since 2013, with 968 fatal overdoses in 2022, according to preliminary data from the Virginia Department of Health, a 20 percent increase over 2021. Of those, four in five included fentanyl — prescription, illicit or analog — a driving force behind the fatalities.
Researchers at the ...
University of Kentucky physicians push for standard-of-care opioid treatment for incarcerated patients
2023-05-13
In a recently published commentary, UK HealthCare physicians call for standard-of-care treatment for opioid use disorder (OUD) among patients who are incarcerated.
The viewpoint article by Anna-Maria South, M.D., Laura Fanucchi, M.D., and Michelle Lofwall, M.D., published in JAMA April 24 highlights the barriers to initiating medication for opioid use disorder (MOUD) among people who are incarcerated.
For patients with opioid use disorder, medications such as buprenorphine and methadone are considered by the medical community as standard of care treatments, as they alleviate withdrawal symptoms, reduce cravings and pain, ...
Fear of childbirth exacerbated by the COVID-19 pandemic
2023-05-13
The COVID-19 pandemic exacerbated fear of childbirth among pregnant people in the U.S., according to a new Dartmouth study.
The researchers were particularly interested in understanding, from a U.S. context, which factors predict childbirth fear and how the pandemic has affected this fear and birth outcomes. The findings are published in Evolution, Medicine, and Public Health.
"Our results showed really high rates of childbirth fear in our sample," says first author Zaneta Thayer '08, an associate professor of anthropology at Dartmouth. "Since there's no pre-pandemic U.S. data, we cannot compare our data to that context but we know that ...
Restoring control to a particular brain region may help to prevent return to use of opioids
2023-05-13
A team of neuroscientists at the Medical University of South Carolina (MUSC) has identified changes in the activity of brain cells known as pyramidal neurons, which contribute to drug seeking in a preclinical model of opioid use disorder. After access to heroin was stopped, these neurons became more excitable. The activity of these neurons was restored to normal by blocking the enzyme protein kinase A (PKA). Inhibiting this enzyme also reduced opioid-seeking behavior. Jacqueline McGinty, Ph.D., professor of neuroscience, and Saurabh Kokane, Ph.D., a postdoctoral scholar in McGinty’s laboratory, recently published their team’s findings in the Journal of Neuroscience.
The risk ...
Stress hormone during pregnancy may improve early language development in children
2023-05-13
High levels of the stress hormone cortisol during the third trimester of pregnancy may improve speech and language skills in the first 3 years of a child’s life, according to research presented at the 25th European Congress of Endocrinology in Istanbul. The findings help researchers further understand the role cortisol plays in both fetal and child development.
Language development during early childhood can indicate how well a baby’s nervous system was developed in the womb. Prenatal exposure to cortisol – a steroid hormone that helps the body respond to ...
Steroids linked to long-lasting heart disease risk and worse quality of life
2023-05-13
Anabolic steroids not only can cause serious side effects during use, such as heart failure and depression, but can continue being harmful years after stopping, according to two studies presented at the 25th European Congress of Endocrinology in Istanbul. These studies, supported by the Novo Nordisk Foundation, were carried out by researchers from the Copenhagen University Hospital Rigshospitalet who investigated the impact of anabolic steroids in former users.
Anabolic steroids – synthetic hormones ...
Low levels of vitamin D linked to long COVID
2023-05-13
Long COVID risk has been found to increase with low levels of vitamin D, according to research presented at the 25th European Congress of Endocrinology in Istanbul. The findings suggest that individuals should have their vitamin D levels checked after COVID-19.
Also known as post COVID-19 syndrome, long COVID is a new condition in which the effects of COVID-19 last for more than 12 weeks after contracting the initial infection. Studies have shown that it affects 50-70% of patients previously hospitalised for COVID-19, yet very little is known about the condition. One risk factor for worse outcomes for hospitalised COVID-19 patients, such as intubation and mechanical ventilation ...